Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China

BACKGROUND: Regimens involving direct-acting antiviral agents (DAAs) are recommended for the treatment of infection with hepatitis C virus (HCV) genotypes 1, 2 and 3. But real-world data is still not enough, especially in Asia. AIM: To investigate the efficacy and safety of DAA-based regimens in a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ying, Wu, Feng-Ping, Wang, Wen-Jun, Shi, Juan-Juan, Li, Ya-Ping, Zhang, Xin, Dang, Shuang-Suo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886016/
https://www.ncbi.nlm.nih.gov/pubmed/31802834
http://dx.doi.org/10.3748/wjg.v25.i44.6551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886016/
https://www.ncbi.nlm.nih.gov/pubmed/31802834
http://dx.doi.org/10.3748/wjg.v25.i44.6551

Ejemplares similares